Jürgen Bosch

10PUBLICATIONS
39CO-AUTHORS
GlycoconjugatesNanotoxicology, health and safetyNanomedicineMolecular targetsCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Jun 29, 2026
Cellular engagement of the SARS-CoV-2 macrodomain by GS-441524 and enhanced in vitro inhibition by its diphosphorylated metabolite.

|Oct 08, 2025
Non-neutralizing antibodies against SARS-CoV-2 nucleocapsid protein mediate variant transcendent antibody-dependent cellular cytotoxicity.

Anthonia E Osuagwu, Michael Payne, Jürgen Bosch

|Dec 05, 2024
Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages.

Anna C Winnicki, Melanie H Dietrich, Lee M Yeoh

|Jan 21, 2022
The Conserved Macrodomain Is a Potential Therapeutic Target for Coronaviruses and Alphaviruses.

Anthony K L Leung, Diane E Griffin, Jürgen Bosch

|Dec 14, 2021
High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain.

Morgan Dasovich, Junlin Zhuo, Jack A Goodman

|Apr 20, 2018
Chromobacterium spp. mediate their anti-Plasmodium activity through secretion of the histone deacetylase inhibitor romidepsin.

Raúl G Saraiva, Callie R Huitt-Roehl, Abhai Tripathi

Pageof 2

Frequent Collaborators

3 joint publications

Anthony K L Leung

2 joint publications

Christopher L King

2 joint publications

Takashi Tsukamoto

2 joint publications

Junlin Zhuo